About this Research Topic
In recent years, many advances have emerged in immunological research and immunotherapy, including immune checkpoint blockades (ICBs), adoptive immune cell therapy, tumor vaccines and oncolytic viruses, showing great potential in improving the unfavorable prognosis of some cancers. Moreover, with the deepening understanding of tumor microenvironment (TME), which plays a vital role in tumorigenesis, progression, metastasis, and therapeutic resistance, exploring the underlying mechanisms involved in intercellular interaction between cancer cells and immune cells in TME such as T cells and macrophages and developing new potential therapeutic targets in TME have been recognized as of great importance for developing cancer immunotherapy.
However, many problems remain concerning TME and immunotherapy for breast cancer. Triple-negative breast cancer (TNBC), as a special breast cancer subtype, exhibits a fairly favorable response to immunotherapy, but the clinical outcomes of immunotherapy for different breast cancer subtypes are quite diverse. It is necessary to explore the mechanism and crucial mediators of immune escape to enhance the effect of current immunotherapy and even to transform non-responders into responders. What is more, how to distinguish non-responders and responders, how to improve the prognosis of responders, and how to detect, identify, and control the irreversible severe immune-related adverse events (IRAEs) such as endocrine disorders, myocarditis to improve treatment safety also need to be studied.
This Research Topic aims to create a collection of the latest research in the field of immunology that advances our understanding of breast cancer and its clinical implications. Studies about basic research, translational research, and clinical trials are welcome. We are interested in Original Research, Clinical Trial, Case Report, Brief Research Report, Review articles, and Systematic reviews, focusing on, but not limited to, the following areas:
• Molecular mechanisms of the intercellular interaction between immune cells in TME and cancer cells
• Biomarkers or strategies related to screening immunotherapy-sensitive populations
• Molecular mechanism of immunotherapy response and drug resistance in breast cancer treatments and strategies for overcoming drug resistance
• Strategies for predicting the effect of immunotherapy on breast cancer patients
• Strategies for controlling the side effects of immunotherapy to improve the treatment
• Clinical experience with immunotherapy in breast cancer
• New immunotherapy approaches for patients with breast cancer: beyond PD-1/PD-L1 blockade
• Microbiome effects on immunotherapy results in breast cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
However, many problems remain concerning TME and immunotherapy for breast cancer. Triple-negative breast cancer (TNBC), as a special breast cancer subtype, exhibits a fairly favorable response to immunotherapy, but the clinical outcomes of immunotherapy for different breast cancer subtypes are quite diverse. It is necessary to explore the mechanism and crucial mediators of immune escape to enhance the effect of current immunotherapy and even to transform non-responders into responders. What is more, how to distinguish non-responders and responders, how to improve the prognosis of responders, and how to detect, identify, and control the irreversible severe immune-related adverse events (IRAEs) such as endocrine disorders, myocarditis to improve treatment safety also need to be studied.
This Research Topic aims to create a collection of the latest research in the field of immunology that advances our understanding of breast cancer and its clinical implications. Studies about basic research, translational research, and clinical trials are welcome. We are interested in Original Research, Clinical Trial, Case Report, Brief Research Report, Review articles, and Systematic reviews, focusing on, but not limited to, the following areas:
• Molecular mechanisms of the intercellular interaction between immune cells in TME and cancer cells
• Biomarkers or strategies related to screening immunotherapy-sensitive populations
• Molecular mechanism of immunotherapy response and drug resistance in breast cancer treatments and strategies for overcoming drug resistance
• Strategies for predicting the effect of immunotherapy on breast cancer patients
• Strategies for controlling the side effects of immunotherapy to improve the treatment
• Clinical experience with immunotherapy in breast cancer
• New immunotherapy approaches for patients with breast cancer: beyond PD-1/PD-L1 blockade
• Microbiome effects on immunotherapy results in breast cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: breast cancer, immunology, immunotherapy, tumor microenvironment, tumor infiltrating lymphocytes
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
